Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors

Contributed by: Business Wire

Logo

Images

Business Wire embedded0

Tags

Health

Genetics

General Health

Research

Science

Pharmaceutical

Biotechnology

Hemlibra

More Like This

PR Newswire associated0

Precision BioLogic Leads the Way in Hemophilia Testing

PR Newswire associated0

Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM

PR Newswire associated0

Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors

PR Newswire associated0

Innovation Through Collaboration Puts Precision BioLogic on the Map in Hemostasis Diagnostics and Research

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate

PR Newswire associated0

Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026

Sobi to showcase new data across haemophilia portfolio at ISTH 2026